Similar companies
Income Statement (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Revenue | 4.16B | 9% |
| Gross Profit | 2.02B | 14.3% |
| Cost of Revenue | 3.89B | 0.3% |
| Operating expense | 2.1B | 4.5% |
| Net Income | -846M | 508.6% |
| EBITDA | 254M | 370.4% |
Balance Sheet (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Total Assets | 41.3B | 3.4% |
| Total Liabilities | 34.8B | 1.3% |
| Total Equity | 6.36B | 12.6% |
| Shares Outstanding | 1.13B | 0.9% |
Cash Flow (USD)
| Q2 '24 | QoQ | |
|---|---|---|
| Cash from operations | 103M | 183.1% |
| Cash from investing | 178M | 23.6% |
| Cash from financing | -966M | 539.7% |
EPS
Financial Highlights for Teva Pharmaceutical in Q2 '24
Teva Pharmaceutical reported a revenue of 4.16B, which is a 9% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 2.02B, marking a 14.3% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 3.89B, a -0.3% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 2.1B, showing a -4.5% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -846M, showing a -508.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was 254M, showing a 370.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Teva Pharmaceutical faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income.
